Skip to content
Credit reportVerdict and grounds
Made on 19-11-2026 at 14:35
Reference CK-0884868444-20261119

BIPHARMA

Dissolved and wound upPublic limited company0884.868.444
financial year to 14 July

Sources: the KBO register on 19-11-2026; the National Bank, annual accounts to 14-07-2026 filed on 04-11-2026; the Belgian Official Gazette, latest deed of 20-07-2026.

Credit verdict
Liquidated
No credit, as BIPHARMA is no longer active
  • Liquidation closed on 14-07-2026.
Checked score
No score
No score for a company that is no longer active.
Bankruptcy probability within 12 months
Checked computes no bankruptcy probability for a company that is no longer active.
Gross margin
-€10,525
€632,427 in 2025
Net result
-€87,683
€500,026 in 2025
Equity
€875,993
▼ 9.1% against 2025
Cash
€1,710
▼ 91.0% against 2025

Grounds

the facts the verdict rests on, each with its source
  1. BIPHARMA is no longer active. Liquidation closed on 14-07-2026.Deed of 20-07-2026 in the Belgian Official Gazette page 4
  2. In the year to 14-07-2026, BIPHARMA made a loss of €87,683.Annual accounts to 14-07-2026 page 2
  3. Equity stands at €875,993, or 100.0% of the balance sheet total of €875,993.Annual accounts to 14-07-2026 page 2

Representation

The signing rule is in the deed of 19-11-2021.

Articles of association, Belgian Official Gazette of 19-11-2021, deed 21367920

Ownership

Checked found no shareholder in the annual accounts, the deeds or the LEI register.

BIPHARMA · 0884.868.444 · credit report of 19-11-2026Page 1 of 5
BIPHARMA0884.868.444 · report of 19-11-2026

Financial situation

Annual accounts 2022 to 2026, as filed with the National Bank

Gross margin and net resultin €m

20220.220230.220240.220250.62026-0.0120220.220230.220240.220250.52026-0.09
gross marginnet result

Equity and debtsin €m

202220232024202520260.90.00
equitydebts

Cashin €m

20220.620230.0220240.120250.0220260.00
on the balance sheet date
Financial year202220232024202520267 monthsTrend
Results
Gross margin€167,454€208,591€216,923€632,427-€10,525
Operating result€167,352€207,522€213,416€627,494-€13,551
Net result€164,816€190,249€193,491€500,026-€87,683
Balance sheet at the closing date
Equity€1.5m€1.7m€847,539€963,676€875,993
Debts€314,138€192,889€133,064€9,117€0
Debts due within one year€314,138€190,228€122,364€6,617€0
Cash€554,458€20,419€100,133€19,102€1,710
Balance sheet total€1.8m€1.8m€980,603€972,793€875,993
Operations
Employees in full-time equivalents---0.00.0
Ratios
Solvency82.3%89.6%86.4%99.1%100.0%
Liquidity5.669.718.01--

Source: Annual accounts to 14-07-2026, abbreviated format, filed on 04-11-2026 (2026-00602612); Annual accounts 2025, abbreviated format, filed on 09-06-2026 (2026-00146352); Annual accounts 2022 to 2024, filed from 30-08-2023 to 08-08-2025 (2023-00417532, 2024-00375714, 2025-00370930).

Debts fell by €9,117 in 2026.

The annual accounts to 14-07-2026 state no amount of overdue tax or social security (RSZ) debts.

The financial year to 14-07-2026 ran for 7 months.

BIPHARMA · 0884.868.444 · credit report of 19-11-2026Page 2 of 5
BIPHARMA0884.868.444 · report of 19-11-2026

Board, signature and ownership

Position on 19-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The signing rule is in the deed of 19-11-2021.

Articles of association, Belgian Official Gazette of 19-11-2021, deed 21367920

Board

last known board
Directoruntil 20-07-2026
Directoruntil 20-07-2026

Ownership and group

Shareholders

Checked found no shareholder in the annual accounts, the deeds or the LEI register.

Board changes

Dissolution with immediate closure of the liquidation. Dissolved and wound up in a single deed. Books and records kept in Breda (5 years). (director) and (director) resign.

Gazette, deed 26347236

. resigns. acts as permanent representative. and appointed. General meeting of 21-02-2023.

Gazette, deed 23042768

and resign. . appointed as sole director. and act as permanent representatives.

Gazette, deed 21367920

(managing director) and (director) reappointed. General meeting of 01-06-2012.

Gazette, deed 14139891
BIPHARMA · 0884.868.444 · credit report of 19-11-2026Page 3 of 5
BIPHARMA0884.868.444 · report of 19-11-2026

Events and comparison

The last 24 months, newest first

Annual accounts 2026 filed, 102 days before the deadline.

NBB filing

Dissolution with immediate closure of the liquidation. Dissolved and wound up in a single deed. Books and records kept in Breda (5 years). (director) and (director) resign.

Gazette, deed 26347236

Annual accounts 2025 filed, 52 days before the deadline.

NBB filing

Highest result from 2007 to 2026. The operating result of €627,494 and the net result of €500,026 are both a record.

Financial

Liquidity more than 18 times. The current ratio rises from 8.01 to 147.01. Short-term debt falls from €122,364 to €6,617.

Financial

Listed in the Peppol Directory.

Annual accounts 2024 filed, 8 days late.

NBB filing

Other findings

Peppol

Reachable for e-invoices since 10-12-2025, under 0208:0884868444.

Sanctions lists

BIPHARMA · 0884.868.444 · credit report of 19-11-2026Page 4 of 5
BIPHARMA0884.868.444 · report of 19-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units19-11-2026KBO 0884.868.444
National Bank of BelgiumAnnual accounts to 14-07-2026, abbreviated format04-11-20262026-00602612
National Bank of BelgiumAnnual accounts 2025, abbreviated format09-06-20262026-00146352
National Bank of BelgiumAnnual accounts 2022 to 202430-08-2023 to 08-08-20252023-00417532, 2024-00375714, 2025-00370930
Belgian Official GazetteLiquidated20-07-2026deed 26347236
Belgian Official GazetteBoard27-03-2023deed 23042768
Belgian Official GazetteArticles of association with the signing rule19-11-2021deed 21367920
Peppol DirectoryRegistration for e-invoices10-12-20250208:0884868444
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name19-11-2026no match

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

BIPHARMA · 0884.868.444 · credit report of 19-11-2026Page 5 of 5